Home » Stocks » Puma Biotechnology

Puma Biotechnology Inc. (PBYI)

Stock Price: $9.92 USD -0.11 (-1.10%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 393.59M
Revenue (ttm) 241.07M
Net Income (ttm) -41.62M
Shares Out 39.68M
EPS (ttm) -1.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $9.92
Previous Close $10.03
Change ($) -0.11
Change (%) -1.10%
Day's Open 10.12
Day's Range 9.71 - 10.21
Day's Volume 835,257
52-Week Range 5.50 - 15.00

More Stats

Market Cap 393.59M
Enterprise Value 398.06M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 39.68M
Float 29.48M
EPS (basic) -1.06
EPS (diluted) -1.06
FCF / Share -0.04
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.82M
Short Ratio 8.88
Short % of Float 23.19%
Beta 1.20
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.63
PB Ratio 43.11
Revenue 241.07M
Operating Income -30.29M
Net Income -41.62M
Free Cash Flow -1.37M
Net Cash -4.46M
Net Cash / Share -0.11
Gross Margin 97.67%
Operating Margin -12.56%
Profit Margin -17.30%
FCF Margin -0.57%
ROA -7.22%
ROE -184.27%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 1
Overweight 0
Hold 6
Underweight 1
Sell 3

Analyst Consensus: Hold

Price Target

$11.67*
(17.64% upside)
Low
6.00
Current: $9.92
High
16.00
Target: 11.67
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue27225127.69-------
Revenue Growth8.47%806.6%--------
Gross Profit23521622.11-------
Operating Income-39.10-94.67-292-277-240-142-54.83-74.45-10.16-0.01
Net Income-75.60-114-292-276-239-142-54.66-74.35-10.23-0.01
Shares Outstanding38.7737.9437.1733.3032.1330.0128.7021.737.754.00
Earnings Per Share-1.95-2.99-7.85-8.29-7.45-4.73-1.90-3.42-1.32-
Operating Cash Flow22.38-24.11-172-142-154-77.20-55.05-44.01-1.82-0.01
Capital Expenditures-0.31-0.61-0.43-7.28-1.18-1.29-0.63-1.06-0.69-
Free Cash Flow22.07-24.71-173-149-156-78.50-55.68-45.07-2.52-0.01
Cash & Equivalents12016586.0223422014385.1613954.440.00
Total Debt12015248.48-------
Net Cash / Debt0.2713.5437.5423422014385.1613954.440.00
Assets23525916625324016310415255.40-
Liabilities21722511242.9733.8445.7120.3922.791.03-
Book Value17.4634.3153.3021020611783.9912954.37-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Puma Biotechnology Inc.
Country United States
Employees 269
CEO Alan H. Auerbach

Stock Information

Ticker Symbol PBYI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PBYI

Description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.